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TObjective: Significant cardiac dysfunction after brain death leading to exclusion
from procurement for cardiac transplantation is seen in up to 25% of potential organ
donors in the absence of structural heart disease. The cause includes uncoupling of
the myocardial -adrenergic receptor signaling system. The mechanism, however,
has not yet been described. This study investigates our hypothesis that brain death
causes acute activation of the AR kinase and leads to desensitization of myocardial
-adrenergic receptors and impaired ventricular function.
Methods: Adult pigs underwent a sham operation or induction of brain death by
means of subdural balloon inflation (n  8 in each group). Cardiac function was
assessed by using sonomicrometry at baseline and for 6 hours after the operation.
-Adrenergic receptor signaling was assessed at 6 hours after the operation by
measuring myocardial sarcolemmal membrane adenylate cyclase activity, -adren-
ergic receptor density, -adrenergic receptor kinase expression, and activity.
Results: Induction of brain death led to significantly decreased left ventricular systolic
and diastolic function. Basal and isoproterenol-stimulated adenylate cyclase activity was
blunted in the brain dead group compared with the sham-operated group (28.3 4.3 vs
48.3 7.6 pmol of cyclic adenosine monophosphate · mg1 · min1 [P .01] and 54.8
 9.6 vs 114.5  18 pmol of cyclic adenosine monophosphate · mg1 · min1 [P 
.02]). There was no difference in -adrenergic receptor density between the brain dead
and sham-operated groups. Myocardial -adrenergic receptor kinase expression was
3-fold greater in the brain dead versus sham-operated groups, and membrane -adren-
ergic receptor kinase activity was 2.5-fold greater in the brain dead group compared with
that seen in the sham-operated group.
Conclusion: Induction of brain death leads to significant left ventricular dysfunction
in this porcine model. Cardiac -adrenergic receptors are clearly uncoupled after
brain death, and our data suggest that the mechanism is acute increase of myocardial
-adrenergic receptor kinase activity, leading to -adrenergic receptor desensitiza-
tion and ventricular dysfunction.
The incidence of heart failure (HF) continues to increase in the United States andworldwide. Despite advances in medical therapy, the average survival for pa-tients given a diagnosis of HF is only approximately 5 years. The most effective
long-term therapy for end-stage HF is cardiac transplantation. Despite the excellent
outcomes after transplantation, this remains an extremely limited option because of the
donor organ shortage. Adding to the problem, nearly 25% of potential heart donors
without evidence of structural heart disease are found to have significantly decreased
myocardial function and therefore are not considered for procurement. The cause of
ventricular dysfunction after brain death (BD) is likely multifactorial, and previously
reported hypotheses include ischemic injury, direct catecholamine-induced myocardial
injury, and impaired -adrenergic receptor (AR) signaling. Although uncoupling of
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the mechanism underlying the impairment of this critical sig-
naling system has not. G protein–coupled receptor kinases
(GRKs) are serine-threonine kinases that phosphorylate ago-
nist-occupied G protein–coupled receptors and lead to receptor
desensitization. GRK2 or AR kinase 1 (ARK1) is abun-
dantly expressed in the heart and plays an important role in
regulating AR signaling and cardiac function. We hypothe-
size that the catecholamine surge resulting from BD leads to
activation of myocardial ARs and subsequent activation of
ARK1. This leads to desensitization of myocardial ARs and
decreased ventricular function. In this study we used a vali-
dated porcine model of BD and ventricular dysfunction to
determine the mechanism of AR uncoupling. Inhibition of
myocardial AR desensitization in this clinical setting might
lead to an expanded donor organ population.
Materials and Methods
Induction of BD
All animals received humane care in compliance with the “Prin-
ciples of laboratory animal care” formulated by the National
Society for Medical Research and the “Guide for the care and use
of laboratory animals” prepared by the Institute of Laboratory
Animals Resources and published by the National Institutes of
Health (National Institutes of Health publication no. 86-23, revised
1985). The Animal Care and Use Committee at Children’s Hos-
pital Research Foundation also approved the protocol.
Crossbred adolescent pigs (20-35 kg) were anesthetized with
ketamine (20 mg/kg administered intramuscularly) and aceproma-
zine (1.1 mg/kg administered intramuscularly), intubated, and ven-
tilated. Deep sedation and paralysis were maintained with an
infusion of sodium pentobarbital (20 mg · kg1 · h1), intermittent
fentanyl (10 g · kg1 · h1), and intermittent pancuronium (200
g · kg1 · h1). A 22F Fogarty occlusion catheter (Baxter, Irvine,
Calif) and an open lumen pressure catheter (Medtronic, Minneap-
olis, Minn) were placed into the subdural space through a fronto-
parietal burr hole. A LaserFlo laser Doppler blood perfusion mon-
itor (Vasamedics, St Paul, Minn) was inserted directly into the
brain. By using percutaneous electrodes, a 5-lead electroencepha-
lography monitor was placed. Through a median sternotomy,
piezoelectric ultrasound crystals (Sonometrics, London, Ontario,
Canada) were placed in 3 axes on the heart to monitor cardiac
Abbreviations and Acronyms
AC  adenylate cyclase
ANOVA  analysis of variance
ATP  adenosine triphosphate
BD  brain death
cAMP  cyclic adenosine monophosphate
GRK  G protein–coupled receptor kinases
HF  heart failure
LV  left ventricular
PRSW  preload recruitable stroke work.function. Pressure transducer–tipped 2F or 3F catheters (Millar
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the pulmonary artery. The subdural balloon was then inflated with
25 mL of water over 1 minute to induce BD, which was confirmed
by means of electroencephalography and correlated with changes
in laser-detected blood flow. Cardiopulmonary function and intra-
cranial pressure were monitored continuously throughout the ex-
periment. Arterial blood gas, electrolytes, and pH were checked,
and blood samples were collected at baseline; 0, 2, 4, 6, 10, 15, 30,
and 60 minutes after BD; and then hourly for 6 hours (Bayer
Diagnostics, East Walpole, Mass). Left ventricular (LV) end-
diastolic volume was kept constant. After 6 hours of BD and
observation, the animals were killed with sodium pentobarbital,
and myocardial specimens were obtained.
Analysis of Cardiac Function
The Cardiosoft data analysis software (Sonometrics) determined the
derivative of the change in pressure over time and pressure-volume
relationships. Preload recruitable stroke work (PRSW) was calculated
from data collected during transient inferior vena caval occlusion. 1
Protein Immunoblotting
Tissue was homogenized in ice-cold lysis buffer (25 mmol/L
Tris-HCl [pH 7.5], 5 mmol/L ethylenediamine tetraacetic acid, 5
mmol/L ethyleneglycol-bis-(-aminoethylether)-N,N,N=, N=-tet-
raacetic acid, 10 g/mL leupeptin, 20 g/mL aprotinin, and 1
mmol/L phenylmethylsulfonyl fluoride). Nuclei and tissue were
separated by means of centrifugation at 800g for 20 minutes. The
crude supernatant was then centrifuged at 20,000g for 20 minutes.
Protein concentrations were determined on the supernatant (cyto-
solic fraction). Sedimented proteins (membrane fraction) were
resuspended in 50 mmol/L HEPES (pH 7.3) and 5 mmol/L MgCl2.
The immunodetection of myocardial levels of ARK1 (GRK2,
polyclonal rabbit IgG; Santa Cruz Biotechnology, Inc, Santa Cruz,
Calif) was performed on an equal amount of protein from cytosolic
and membrane extracts (80 g) electrophoresed through 12%
Tris-glycine gels and transferred to nitrocellulose. Membranes
were blocked in 5% nonfat dried milk in 0.1% Tween 20 in
phosphate-buffered saline for 1 hour at room temperature. The
protein was visualized with a horseradish peroxidaselinked sec-
ondary antibody and ECL detection (Amersham, Piscataway, NJ).
GRK Activity by Rhodopsin Phosphorylation
The membrane fractions of the myocardial extracts were used to
determine GRK activity. Extracts (100 g of protein) were incubated
with rhodopsin-enriched rod outer-segment membranes in reaction
buffer containing the following: MgCl2, 10 mmol/L; Tris-HCl, 20
mmol/L; ethylenediamine tetraacetic acid, 2 mmol/L; ethyleneglycol-
bis-(-aminoethylether)-N,N,N=, N=-tetraacetic acid, 5 mmol/L;
and adenosine triphosphate [ATP], 0.1 mmol/L (containing
[-32P]ATP), as previously described.2 After incubating in white light
for 15 minutes at room temperature, reactions were quenched with
ice-cold lysis buffer and centrifuged for 15 minutes at 13,000g.
Sedimented proteins were resuspended in 25 L of protein gel load-
ing dye and treated with 12% sodium dodecylsulfate–polyacrylamide
gel electrophoresis. Phosphorylated rhodopsin was visualized by us-
ing autoradiography of dried polyacrylamide gels and quantified with
a Molecular Dynamics PhosphorImager.
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Total AR density was determined by incubating 25 g of cardiac
sarcolemmal membranes with a saturating concentration of [125I]-
labeled cyanopindolol and 20 mol/L alprenolol to define nonspe-
cific binding. Sarcolemmal membrane samples from brain dead
and control animals were done in triplicate with 300 pmol/L of
[125I]-labeled cyanopindolol in 250 L of binding buffer (50
mmol/L HEPES [pH 7.3], 5 mmol/L MgCl2, and 0.1 mmol/L
ascorbic acid). Assays were done at 37°C for 1 hour and then
filtered over GF/C glass fiber filters (Whatman, Middlesex, United
Kingdom) that were washed twice and counted in a gamma
counter. Data were analyzed by using nonlinear least-square curve
fit (GraphPad Prism; GraphPad, San Diego, Calif).
Adenylyl Cyclase Activity
Cardiac sarcolemmal membranes (20 g of protein) were incu-
bated for 15 minutes at 37°C with [-32P]ATP under basal con-
ditions, 10-4 mol/L isoproterenol, or 10 mmol/L sodium fluoride.
Cyclic adenosine monophosphate (cAMP) production was quanti-
fied by using standard methods described previously.3
Statistical Analysis
Repeated-measures analysis of variance (ANOVA) was used to
analyze serial data over time within treatment groups. Analyses
were conducted with Statview 4.01 software (Abacus Concepts
Inc, Berkley, Calif). Experimental groups were compared by using
the Student t test or 1-way ANOVA, as appropriate. The Bonfer-
roni test was applied to all significant ANOVA results by using
SigmaStat software (Systat Software, Point Richmond, Calif). P
values of less than .05 were considered statistically significant. All
results are expressed as means  SEM.
Results
In Vivo Cardiac Physiology
Induction of BD was performed by means of subdural
inflation of a Fogarty balloon, and BD itself was observed
on the basis of electroencephalographic changes and the
consequent hemodynamic instability characterized by the
Cushing reflex. PRSW, a load-independent measure of ven-
tricular function, was measured during transient vena caval
occlusion at the above-mentioned time points. At baseline,
both brain dead and sham-operated animals had similar
PRSW values (43.3  3.1 vs 47.5  4.6; Figure 1, A). In
contrast, PRSW was significantly decreased 6 hours after
BD compared with that seen in sham-operated animals (21.4
 3.3 vs 36.9  3.4, P  .02; Figure 1, A), indicating
marked decrease in LV function after BD. Consistent with
these findings, there was a significant decrease in LV PRSW
6 hours after BD compared with the baseline function for
this group (21.4  3.4 vs 43.3  3.1, P  .01). Similarly,
LV dP/dTmin, a measure of diastolic function, was signifi-
cantly impaired 6 hours after BD compared with that seen in
sham-operated animals (250  38 vs 541  31 mm
Hg/s, P  .02; Figure 1, B). These indices of both systolic
and diastolic function indicate impaired myocardial contrac-
The Journal of Thoracictility after BD and are consistent with previously described
animal models.4,5
Myocardial AR Signaling
We assessed receptor-effector coupling in sarcolemmal
Figure 1. A, Left ventricular preload recruitable stroke work
(PRSW) at baseline and after sham operation or induction of brain
death. *P < .05 versus sham operation and baseline drain death.
#P  not significant versus baseline sham operation. Diamonds,
Sham operation (n  8); squares, BD (n  8). B, Left ventricular
dP/dTmin at baseline and after sham operation or induction of BD.
*P < .05 versus sham operation. #P < .05 versus baseline BD.
Diamonds, Sham operation (n  8); squares, BD (n  8).membranes from hearts of brain dead and sham-operated
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examine the biochemical effects of BD on the myocardial
AR signaling cascade. Basal AC activity was diminished
in the BD group compared with sham-operated animals
(28.3 4.3 vs 48.3 7.6 pmol of cAMP · mg1 · min1, P
 .01; Figure 2). Isoproterenol-stimulated AC activity was
also significantly blunted in the BD group (54.8  9.6 vs
114.5  18.8 pmol of cAMP · mg1 · min1, P  .02;
Figure 2). AC activity stimulated by sodium fluoride, which
induces maximal stimulation of the Gs protein, was similar
in both the BD and sham-operated groups (160.3  43 vs
196  45.2 pmol/mg/min; Figure 2). This blunting of basal
and agonist-stimulated AC activity suggests that uncoupling
of myocardial ARs occurs within 6 hours of BD. Further-
more, there was no significant difference in the maximal
stimulation achieved with sodium fluoride between groups,
Figure 2. Myocardial sarcolemmal membrane adenylate cyclase
activity 6 hours after sham operation or induction of BD. ISO, 10-4
mol/L isoproterenol; NaF, 50 mmol/L sodium fluoride. Open col-
umns, Sham operation (n  8); filled columns, BD (n  8). *P <
.03 versus sham operation. cAMP, Cyclic adenosine
monophosphate.
Figure 3. Myocardial sarcolemmal membrane -adrenergic re-
ceptor (AR) density at 6 hours after sham operation (Sh) or
induction of brain death (BD; n  8 in each group performed in
triplicate). P  not significant between groups.
1186 The Journal of Thoracic and Cardiovascular Surgery ● Octsuggesting that the AC effector itself is intact in both brain
dead and sham-operated animals and that uncoupling is
occurring at the receptor–G protein level.
Myocardial AR Density and G Protein Expression
Total myocardial sarcolemmal membrane AR density was
measured 6 hours after induction of BD, and there was no
difference between the BD and sham-operated groups
(121.5  31 vs 132.15  14.7 fmol/mg; Figure 3). Protein
immunoblotting was performed to determine whether any
differences were present between groups in G protein ex-
pression. There was no difference between groups in Gs or
Gi expression (data not shown). This suggests that the AR
uncoupling is not due to altered expression of either Gs or
Gi, which stimulate or inhibit AC activity, respectively.
Myocardial GRK Expression and Activity
Myocardial ARK1 expression in the membrane fraction 6
hours after BD was enhanced compared with that seen in the
sham-operated group (20.7 3.2 vs 6.7 1.5 densitometry
units, P  .05; Figure 4). There was no difference between
groups in total myocardial ARK1 expression (data not
shown). The increase in ARK1 expression in the mem-
brane fraction after BD was also consistent with an increase
in myocardial membrane GRK activity, as measured by
using rhodopsin phosphorylation (20.8 1.0 [BD group] vs
8.9  0.85 [sham-operated group] densitometry units, P 
.02; Figure 5). We also examined LV myocardial membrane
expression of GRK5, the other GRK in the heart, by means
of protein immunoblotting and found no difference between
the BD and sham-operated groups (data not shown). The
relative expression of GRK5 was very low compared with
ARK1 in myocardial membrane fractions.
Discussion
Cardiac transplantation remains the best long-term treat-
ment for patients with end-stage HF. Unfortunately, it re-
Figure 4. Myocardial sarcolemmal membrane -adrenergic re-
ceptor kinase (ARK1) protein expression at 6 hours after sham
operation (Sh) or induction of brain death (BD; n  8 in each
group). *P < .05 versus sham operation.mains an epidemiologically trivial therapy for this disease
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extremely limited. Each year in the United States alone,
only approximately half of the patients on the waiting list
undergo heart transplantation, and patient criteria for listing
are very strict because of the critical donor limitations.6
Adding to the problem of a limited number of potential
organ donors is donor heart dysfunction. Up to 25% of
potential heart donors are found to have severely decreased
cardiac function after BD in the absence of structural or
ischemic heart disease.7 Because of the morbidity and mor-
tality associated with early graft dysfunction and with ques-
tionable recovery of ventricular function, these organs are
seldom used. The cause of donor heart dysfunction is likely
multifactorial and might include ischemic injury,8 increased
free radical formation, direct catecholamine-induced myo-
cardial injury, and impaired AR signaling,9,10 resulting in
ventricular dysfunction after BD. Desensitization of the
AR signaling system has been reported in human donor
heart dysfunction9 and animal models of BD,10 but the
mechanism underlying this defect has not been described.
This is the first report that comprehensively investigates
multiple levels of the AR signaling system in a model of
BD with ventricular dysfunction. In this study we demon-
strate that there is significant desensitization and uncoupling
of myocardial ARs after BD as a result of an acute in-
crease in the activity of ARK1, which is a critical modu-
lator of AR signaling and cardiac function.
The myocardial AR signaling pathway plays a critical
role in the regulation of cardiac contractility. ARs are the
primary myocardial targets of the sympathetic neurotrans-
mitter norepinephrine and the adrenal hormone epinephrine.
Activation of ARs in the heart by these 2 catecholamines
leads to positive chronotropic and inotropic action through
stimulation of adenylyl cyclase and subsequent increases in
cAMP and intracellular Ca2 release.11 Continued exposure
of ARs to agonists results in a rapid decrease in respon-
siveness, which is known as desensitization.12 Agonist-
dependent desensitization can be initiated by the phosphor-
ylation of activated receptors by members of the family of
GRKs.13 The AR kinase 1 (ARK1 or GRK2) is a GRK
that specifically phosphorylates activated 1- and 2-ARs,
leading to desensitization in vitro and in vivo. It is becoming
increasingly more evident that ARK1 plays a critical role
in myocardial function. Alteration of myocardial ARK1
activity can have profound effects on in vivo cardiac per-
formance. Recent studies have described decreased cardiac
contractility in transgenic mice with cardiac-specific over-
expression of ARK114 and restoration of or enhanced AR
signaling and cardiac function resulting from inhibition of
increased myocardial ARK1 both in vitro15,16 and in
vivo.14,17-19
Decreased myocardial function after BD leading to ex-
clusion from procurement is not an uncommon clinical
The Journal of Thoracicsituation. There is a well-described catecholamine surge
associated with the induction of BD, which leads to an
initial hypertensive and tachycardic state. In an animal
model of BD, circulating dopamine, epinephrine, and nor-
epinephrine concentrations were increased by 800%, 700%,
and 100% respectively.20 These levels are similar to those
seen in the clinical situation.21 A study of human hearts with
significant donor heart dysfunction established that AR
desensitization and uncoupling was present after BD, as
demonstrated by diminished response to -agonist stimula-
tion and blunted agonist-stimulated AC activity.9 This in-
dicated that AR desensitization might play an important
role in donor heart dysfunction.
We sought to define the mechanism of AR uncoupling
and myocardial dysfunction after BD. In the present study
we used a valid and reproducible porcine model of BD.4
With constant loading conditions, LV systolic and diastolic
function were significantly decreased at 6 hours after induc-
tion of BD compared with that seen in sham-operated con-
trol animals. Six hours after BD, we studied myocardial
AR signaling at multiple levels to determine whether
desensitization was contributing to ventricular dysfunction
in the BD group. Basal and isoproterenol-stimulated myo-
cardial sarcolemmal membrane AC activity was blunted in
the BD group compared with that seen in the sham-operated
control animals. This finding clearly indicates significant
functional uncoupling, or desensitization, of ARs after BD
in this model. Ligand binding was performed on myocardial
membrane preparations to determine whether downregula-
tion of ARs was present to account for the decrease in AC
activity. We found no difference in total AR density be-
tween the BD and sham groups, indicating that AR down-
regulation was not present. Expression of the AC-
Figure 5. Myocardial sarcolemmal membrane G protein–coupled
receptor kinase activity at 6 hours after sham operation (Sh) or
induction of brain death (BD; n  8 in each group). *P < .02
versus sham operation.stimulatory G protein subunit Gs and the inhibitory subunit
and Cardiovascular Surgery ● Volume 130, Number 4 1187
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no differences between groups was present. A decrease in
Gs or an increase in Gi expression could also lead to
impaired AC activation by ARs.22 Because ARK1 trans-
location from the cytosolic fraction to the membrane frac-
tion is necessary for targeting ARs, we assessed myocar-
dial membrane ARK1 expression by means of
immunoblotting and found a 3-fold increase in the BD
group versus the control group. Total myocardial ARK1
expression was not different between groups. Rhodopsin
phosphorylation assays were performed on membrane prep-
arations to specifically assess myocardial GRK activity, and
there was a 2.5-fold increase in membrane GRK activity
after BD compared with that seen in sham-operated control
hearts. We conclude from these data that enhanced myocar-
dial ARK1 activity is the primary mechanism responsible
for acute AR desensitization present after BD.
Modulation of cardiac ARK1 activity with the goal of
restoration of AR signaling and ventricular function has
been reported by our laboratory and others using novel
experimental approaches.16,17,23 Inhibition of myocardial
ARK1 activity could be a useful strategy to increase the
number of potential cardiac donors suitable for procurement
and transplantation. The acute increase in circulating cat-
echolamines and stimulation of myocardial ARs that ac-
companies BD appears to lead to activation of ARK1 with
subsequent receptor uncoupling. The degree to which AR
signaling is impaired and the subsequent effect on cardiac
function is clearly variable between potential organ donors
and also depends on baseline cardiac function. Several
reports have described inhibition of myocardial ARK1
activity by using a protein derived from the COOH-
terminus region of ARK1 (ARKct).24 By using trans-
genic models or gene therapy, inhibition of ARK1 activity
in the heart enhances AR coupling and ventricular func-
tion, particularly in the setting of experimental chronic
HF.16,17,23 In addition, we have previously reported on
-adrenergic–based gene therapy to the transplanted heart
ex vivo to increase cardiac 2-AR density by using adeno-
viral-mediated transgene delivery.25 Even more relevant to
our study, use of an adenoviral vector to deliver the ARKct
transgene to the rabbit heart ex vivo led to improved ven-
tricular function in the allograft after transplantation.26 The
initial sympathetic hyperactivity might be attenuated to
some degree with the use of a short-acting -blocker, such
as esmolol. One effect and potential therapeutic mechanism
of chronic -blockade is attenuation of myocardial ARK1
activity.27 However, the acute effect of this therapy on GRK
activity has not been studied. It is likely that a pharmaceu-
tical inhibitor of ARK1 activity might someday become
available that could have a large effect on the medical
therapy of chronic HF. In addition, this strategy might be
1188 The Journal of Thoracic and Cardiovascular Surgery ● Octvery useful to prevent AR desensitization and potential
cardiac dysfunction in the setting of BD.
This is the first report to describe enhanced ARK1
activity as the mechanism of AR uncoupling and associ-
ated myocardial dysfunction after BD. Future studies to
investigate the potentially beneficial effects of acute
ARK1 inhibition appear warranted.
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